143 related articles for article (PubMed ID: 32798651)
21. Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors.
Wang L; Qi J; Fan M; Yao L
Chem Biol Drug Des; 2021 Dec; 98(6):969-978. PubMed ID: 34581498
[TBL] [Abstract][Full Text] [Related]
22. Design, Synthesis, and Evaluation of the Kinase Inhibition Potential of Pyridylpyrimidinylaminophenyl Derivatives.
Manchanda P; Parshad B; Kumar A; Tiwari RK; Shirazi AN; Parang K; Sharma SK
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28317151
[TBL] [Abstract][Full Text] [Related]
23. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.
Ochiana SO; Pandarinath V; Wang Z; Kapoor R; Ondrechen MJ; Ruben L; Pollastri MP
Eur J Med Chem; 2013 Apr; 62():777-84. PubMed ID: 22889561
[TBL] [Abstract][Full Text] [Related]
24. Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
Ray P; Wright J; Adam J; Bennett J; Boucharens S; Black D; Cook A; Brown AR; Epemolu O; Fletcher D; Haunso A; Huggett M; Jones P; Laats S; Lyons A; Mestres J; de Man J; Morphy R; Rankovic Z; Sherborne B; Sherry L; van Straten N; Westwood P; Zaman GZ
Bioorg Med Chem Lett; 2011 Jan; 21(1):97-101. PubMed ID: 21145740
[TBL] [Abstract][Full Text] [Related]
25. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.
Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D
Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148
[TBL] [Abstract][Full Text] [Related]
26. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors.
Bhattacharya SK; Aspnes GE; Bagley SW; Boehm M; Brosius AD; Buckbinder L; Chang JS; Dibrino J; Eng H; Frederick KS; Griffith DA; Griffor MC; Guimarães CR; Guzman-Perez A; Han S; Kalgutkar AS; Klug-McLeod J; Garcia-Irizarry C; Li J; Lippa B; Price DA; Southers JA; Walker DP; Wei L; Xiao J; Zawistoski MP; Zhao X
Bioorg Med Chem Lett; 2012 Dec; 22(24):7523-9. PubMed ID: 23153798
[TBL] [Abstract][Full Text] [Related]
28. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
Patel RA; Forinash KD; Pireddu R; Sun Y; Sun N; Martin MP; Schönbrunn E; Lawrence NJ; Sebti SM
Cancer Res; 2012 Oct; 72(19):5025-34. PubMed ID: 22846914
[TBL] [Abstract][Full Text] [Related]
29. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
30. Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors.
Akama T; Dong C; Virtucio C; Sullivan D; Zhou Y; Zhang YK; Rock F; Freund Y; Liu L; Bu W; Wu A; Fan XQ; Jarnagin K
J Pharmacol Exp Ther; 2013 Dec; 347(3):615-25. PubMed ID: 24049062
[TBL] [Abstract][Full Text] [Related]
31. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
Wu F; Büttner FH; Chen R; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Paw Z; Prokopowicz A; Shih CK; Snow R; Young E; Cywin CL
Bioorg Med Chem Lett; 2010 Jun; 20(11):3235-9. PubMed ID: 20462760
[TBL] [Abstract][Full Text] [Related]
32. Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.
Chae E; Shin YJ; Ryu EJ; Ji MK; Ryune Cho N; Lee KH; Jeong HJ; Kim SJ; Choi Y; Seok Oh K; Park CE; Soo Yoon Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):2134-9. PubMed ID: 23434029
[TBL] [Abstract][Full Text] [Related]
33. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological characterization of selective LIMK inhibitors.
Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Vanormelingen J; Fransen S; Van de Velde S; Defert O
Bioorg Med Chem Lett; 2015 Sep; 25(18):4005-10. PubMed ID: 26233434
[TBL] [Abstract][Full Text] [Related]
35. 5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
[TBL] [Abstract][Full Text] [Related]
36. Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase.
Rosen MD; Woods CR; Goldberg SD; Hack MD; Bounds AD; Yang Y; Wagaman PC; Phuong VK; Ameriks AP; Barrett TD; Kanelakis KC; Chuang JC; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6548-51. PubMed ID: 19854648
[TBL] [Abstract][Full Text] [Related]
37. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats.
Ginn JD; Bosanac T; Chen R; Cywin C; Hickey E; Kashem M; Kerr S; Kugler S; Li X; Prokopowicz A; Schlyer S; Smith JD; Turner MR; Wu F; Young ER
Bioorg Med Chem Lett; 2010 Sep; 20(17):5153-6. PubMed ID: 20678931
[TBL] [Abstract][Full Text] [Related]
38. Pyrazoles, 1,2,4-triazoles, and tetrazoles as surrogates for cis-amide bonds in boronate ester thrombin inhibitors.
Duncia JV; Santella JB; Higley CA; VanAtten MK; Weber PC; Alexander RS; Kettner CA; Pruitt JR; Liauw AY; Quan ML; Knabb RM; Wexler RR
Bioorg Med Chem Lett; 1998 Apr; 8(7):775-80. PubMed ID: 9871540
[TBL] [Abstract][Full Text] [Related]
39. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
40. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
